{
    "data": [
        {
            "id": "243693",
            "type": "article",
            "attributes": {
                "publishOn": "2010-12-27T13:23:32-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Six Reasons Pfizer Is a Generational Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23864",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/243693-six-reasons-pfizer-is-a-generational-buy"
            }
        },
        {
            "id": "243265",
            "type": "article",
            "attributes": {
                "publishOn": "2010-12-22T13:21:36-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Completes End-Of-Review Meeting With FDA",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23918",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/243265-arena-completes-end-of-review-meeting-with-fda"
            }
        },
        {
            "id": "242442",
            "type": "article",
            "attributes": {
                "publishOn": "2010-12-17T11:03:55-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bill Steere: The Man Who Pulls the Strings at Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/242442-bill-steere-the-man-who-pulls-the-strings-at-pfizer"
            }
        },
        {
            "id": "241345",
            "type": "article",
            "attributes": {
                "publishOn": "2010-12-12T07:00:37-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Analysts Welcome Change at Pfizer's Helm but Want More",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24038",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/241345-analysts-welcome-change-at-pfizers-helm-but-want-more"
            }
        },
        {
            "id": "240515",
            "type": "article",
            "attributes": {
                "publishOn": "2010-12-07T13:18:08-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Can Pfizer's New CEO Help Overcome Loss of Lipitor Revenue?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23864",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/240515-can-pfizers-new-ceo-help-overcome-loss-of-lipitor-revenue"
            }
        },
        {
            "id": "240237",
            "type": "article",
            "attributes": {
                "publishOn": "2010-12-06T10:31:43-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Clock Runs Out for Pfizer CEO",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/240237-clock-runs-out-for-pfizer-ceo"
            }
        },
        {
            "id": "240234",
            "type": "article",
            "attributes": {
                "publishOn": "2010-12-06T10:21:43-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Change of Guard Won't Make a Difference",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/240234-pfizer-change-of-guard-wont-make-a-difference"
            }
        },
        {
            "id": "240157",
            "type": "article",
            "attributes": {
                "publishOn": "2010-12-06T03:48:28-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer CEO Jeff Kindler's Unexpected Resignation Sure to Prompt Speculation Over Recent Issues",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/240157-pfizer-ceo-jeff-kindlers-unexpected-resignation-sure-to-prompt-speculation-over-recent-issues"
            }
        },
        {
            "id": "240053",
            "type": "article",
            "attributes": {
                "publishOn": "2010-12-05T05:55:45-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Planned Compliance Fund May Have Far-Reaching Implications",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/240053-pfizers-planned-compliance-fund-may-have-far-reaching-implications"
            }
        },
        {
            "id": "238815",
            "type": "article",
            "attributes": {
                "publishOn": "2010-11-26T13:28:07-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Loses in Court ... Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/238815-pfizer-loses-in-court-again"
            }
        },
        {
            "id": "237214",
            "type": "article",
            "attributes": {
                "publishOn": "2010-11-17T02:56:06-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Seeks to Accelerate Drug Development Process in New Partnership",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/237214-pfizer-seeks-to-accelerate-drug-development-process-in-new-partnership"
            }
        },
        {
            "id": "237054",
            "type": "article",
            "attributes": {
                "publishOn": "2010-11-16T08:44:38-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Unlikely to Benefit From Surprising New Data on Heart Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/237054-pfizer-unlikely-to-benefit-from-surprising-new-data-on-heart-drug"
            }
        },
        {
            "id": "236705",
            "type": "article",
            "attributes": {
                "publishOn": "2010-11-14T10:48:16-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Trading Below Reproduction Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24169",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "91100",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/236705-pfizer-trading-below-reproduction-value"
            }
        },
        {
            "id": "235947",
            "type": "article",
            "attributes": {
                "publishOn": "2010-11-10T04:41:31-05:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena\u2019s Diet Pill May Encounter Yet Another Issue: Heart Valve Disease",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/235947-arena-s-diet-pill-may-encounter-yet-another-issue-heart-valve-disease"
            }
        },
        {
            "id": "235328",
            "type": "article",
            "attributes": {
                "publishOn": "2010-11-07T09:14:22-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Cost-Cutting Program: Up Next Its $37 Million Jet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/235328-pfizers-cost-cutting-program-up-next-its-37-million-jet"
            }
        },
        {
            "id": "234057",
            "type": "article",
            "attributes": {
                "publishOn": "2010-11-02T10:21:32-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's 3Q Results Disappoint, Revenues Fall Short",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/234057-pfizers-3q-results-disappoint-revenues-fall-short"
            }
        },
        {
            "id": "233849",
            "type": "article",
            "attributes": {
                "publishOn": "2010-11-01T13:33:10-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Earnings Preview: Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21445",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/233849-earnings-preview-pfizer"
            }
        },
        {
            "id": "232113",
            "type": "article",
            "attributes": {
                "publishOn": "2010-10-25T15:58:41-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Investors Still Look for Silver Lining",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/232113-arena-investors-still-look-for-silver-lining"
            }
        },
        {
            "id": "231980",
            "type": "article",
            "attributes": {
                "publishOn": "2010-10-25T08:57:35-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Bad Is the Non-Approval of Arena's Weight Loss Drug?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/231980-how-bad-is-the-non-approval-of-arenas-weight-loss-drug"
            }
        },
        {
            "id": "231926",
            "type": "article",
            "attributes": {
                "publishOn": "2010-10-25T04:13:21-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lorcaserin\u2019s Path to Approval",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23729",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/231926-lorcaserin-s-path-to-approval"
            }
        },
        {
            "id": "231836",
            "type": "article",
            "attributes": {
                "publishOn": "2010-10-24T08:38:56-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena's 'Fat Chance' for Drug Approval: No Surprises There",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/231836-arenas-fat-chance-for-drug-approval-no-surprises-there"
            }
        },
        {
            "id": "231803",
            "type": "article",
            "attributes": {
                "publishOn": "2010-10-24T05:27:08-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer\u2019s Big Generics Bet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/231803-pfizer-s-big-generics-bet"
            }
        },
        {
            "id": "229870",
            "type": "article",
            "attributes": {
                "publishOn": "2010-10-13T12:59:02-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Third Mega-Deal Done, Pfizer Still Needs New Drugs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23478",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/229870-a-third-mega-deal-done-pfizer-still-needs-new-drugs"
            }
        },
        {
            "id": "229551",
            "type": "article",
            "attributes": {
                "publishOn": "2010-10-12T06:18:43-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Opens Radiation Biology R&D Center in Wuhan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20840",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/229551-pfizer-opens-radiation-biology-r-and-d-center-in-wuhan"
            }
        },
        {
            "id": "228464",
            "type": "article",
            "attributes": {
                "publishOn": "2010-10-05T06:31:57-04:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Pharmaceuticals: Investors Smell a Rat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/228464-arena-pharmaceuticals-investors-smell-a-rat"
            }
        },
        {
            "id": "227844",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-30T15:41:52-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Another Setback for Pfizer's Sutent",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/227844-another-setback-for-pfizers-sutent"
            }
        },
        {
            "id": "227382",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-28T07:40:40-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Feds Give Pfizer's Cholesterol Drug Whistle-Blower Lawsuit a Boost",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/227382-feds-give-pfizers-cholesterol-drug-whistle-blower-lawsuit-a-boost"
            }
        },
        {
            "id": "225950",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-19T08:02:15-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Pharma's Diet Pill and Tumors: A Big Rat?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225950-arena-pharmas-diet-pill-and-tumors-a-big-rat"
            }
        },
        {
            "id": "225873",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-19T04:05:02-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "4 Lessons From a Review of Arena Articles",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21825",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225873-4-lessons-from-a-review-of-arena-articles"
            }
        },
        {
            "id": "225844",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-17T19:52:14-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena's Lorcaserin: What Now?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23918",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225844-arenas-lorcaserin-what-now"
            }
        },
        {
            "id": "225769",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-17T10:24:35-04:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Pharmaceuticals\u2019 Lorcaserin Is Down, But Not Necessarily Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23408",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225769-arena-pharmaceuticals-lorcaserin-is-down-but-not-necessarily-out"
            }
        },
        {
            "id": "225422",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-15T16:13:41-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Pharmaceutical's Lorqess: A Briefing Document Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23918",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225422-arena-pharmaceuticals-lorqess-a-briefing-document-analysis"
            }
        },
        {
            "id": "225324",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-15T10:17:27-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Upcoming Verdict on Arena's Obesity Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23183",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225324-the-upcoming-verdict-on-arenas-obesity-drug"
            }
        },
        {
            "id": "225313",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-15T09:38:23-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena: This One-Trick Pony Is Safe to Short",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23253",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "218626",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225313-arena-this-one-trick-pony-is-safe-to-short"
            }
        },
        {
            "id": "225229",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-15T02:55:33-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena's Weight Loss Drug in Trouble",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225229-arenas-weight-loss-drug-in-trouble"
            }
        },
        {
            "id": "225096",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-14T09:59:32-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena's Lorcaserin: Therapeutic Value Zero?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225096-arenas-lorcaserin-therapeutic-value-zero"
            }
        },
        {
            "id": "225048",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-14T05:53:46-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena's Lorqess: A Market Size Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23918",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/225048-arenas-lorqess-a-market-size-analysis"
            }
        },
        {
            "id": "224634",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-12T02:07:04-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Aluminum Content of Infant Formula Remains a Challenge for Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/224634-aluminum-content-of-infant-formula-remains-a-challenge-for-pfizer"
            }
        },
        {
            "id": "224078",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-07T06:19:19-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Acquires FoldRX Pharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/224078-pfizer-acquires-foldrx-pharma"
            }
        },
        {
            "id": "224059",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-07T04:44:01-04:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Analysts Won't Tell You About Arena",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23729",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "90606",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/224059-what-analysts-wont-tell-you-about-arena"
            }
        },
        {
            "id": "223705",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-03T03:54:59-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Could Reface up to 1,000 Lawsuits on HRT Complications",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23993",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/223705-pfizer-could-reface-up-to-1000-lawsuits-on-hrt-complications"
            }
        },
        {
            "id": "223657",
            "type": "article",
            "attributes": {
                "publishOn": "2010-09-03T01:12:54-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Acts on Growing Interest in Niche Drugs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/223657-pfizer-acts-on-growing-interest-in-niche-drugs"
            }
        },
        {
            "id": "221941",
            "type": "article",
            "attributes": {
                "publishOn": "2010-08-24T04:43:18-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Just One Stock: Cash, Cost Savings in Undervalued Large-Cap Pharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23970",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "90525",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/221941-just-one-stock-cash-cost-savings-in-undervalued-large-cap-pharma"
            }
        },
        {
            "id": "219163",
            "type": "article",
            "attributes": {
                "publishOn": "2010-08-06T12:04:52-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Lorcaserin the New Miracle Drug?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23729",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "90398",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/219163-is-lorcaserin-the-new-miracle-drug"
            }
        },
        {
            "id": "218390",
            "type": "article",
            "attributes": {
                "publishOn": "2010-08-03T17:36:58-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Posts a Strong Quarter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/218390-pfizer-posts-a-strong-quarter"
            }
        },
        {
            "id": "218239",
            "type": "article",
            "attributes": {
                "publishOn": "2010-08-03T10:07:19-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Will Earnings Beat Get the Shares Moving?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20073",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/218239-pfizer-will-earnings-beat-get-the-shares-moving"
            }
        },
        {
            "id": "215255",
            "type": "article",
            "attributes": {
                "publishOn": "2010-07-20T02:24:07-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Weight Loss Drug Looks Promising",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23610",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "90278",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/215255-arena-weight-loss-drug-looks-promising"
            }
        },
        {
            "id": "214170",
            "type": "article",
            "attributes": {
                "publishOn": "2010-07-13T03:15:13-04:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vivus, Arena and Orexigen Investors All Worried About Qnexa FDA Panel Review",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23548",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/214170-vivus-arena-and-orexigen-investors-all-worried-about-qnexa-fda-panel-review"
            }
        },
        {
            "id": "211941",
            "type": "article",
            "attributes": {
                "publishOn": "2010-06-25T15:16:12-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Yet Another Pipeline Setback for Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/211941-yet-another-pipeline-setback-for-pfizer"
            }
        },
        {
            "id": "210286",
            "type": "article",
            "attributes": {
                "publishOn": "2010-06-16T05:10:19-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Forms New Unit to Capitalize on Niche Diseases",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/210286-pfizer-forms-new-unit-to-capitalize-on-niche-diseases"
            }
        },
        {
            "id": "209667",
            "type": "article",
            "attributes": {
                "publishOn": "2010-06-11T13:26:17-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Case for Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "90045",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/209667-the-case-for-pfizer"
            }
        },
        {
            "id": "207909",
            "type": "article",
            "attributes": {
                "publishOn": "2010-06-01T14:34:34-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Sells China Swine Vaccine Subsidiary to Harbin",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20840",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/207909-pfizer-sells-china-swine-vaccine-subsidiary-to-harbin"
            }
        },
        {
            "id": "207327",
            "type": "article",
            "attributes": {
                "publishOn": "2010-05-27T12:27:31-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Halts Heart Failure Drug Trial Early on Good News",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/207327-pfizer-halts-heart-failure-drug-trial-early-on-good-news"
            }
        },
        {
            "id": "206468",
            "type": "article",
            "attributes": {
                "publishOn": "2010-05-23T14:16:41-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer, Washington University Collaborate to Find New Uses for Old Drugs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/206468-pfizer-washington-university-collaborate-to-find-new-uses-for-old-drugs"
            }
        },
        {
            "id": "202761",
            "type": "article",
            "attributes": {
                "publishOn": "2010-05-04T11:06:25-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Earnings Boosted by Wyeth Acquisition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/202761-pfizers-earnings-boosted-by-wyeth-acquisition"
            }
        },
        {
            "id": "200178",
            "type": "article",
            "attributes": {
                "publishOn": "2010-04-22T10:38:45-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer for the Long Haul",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21863",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "89785",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/200178-pfizer-for-the-long-haul"
            }
        },
        {
            "id": "197703",
            "type": "article",
            "attributes": {
                "publishOn": "2010-04-08T06:01:41-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer in Asia's Intriguing R&D",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20840",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/197703-pfizer-in-asias-intriguing-r-and-d"
            }
        },
        {
            "id": "197582",
            "type": "article",
            "attributes": {
                "publishOn": "2010-04-07T15:47:20-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Prepares for the Big Lipitor Shake-Up",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21435",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "89710",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/197582-pfizer-prepares-for-the-big-lipitor-shake-up"
            }
        },
        {
            "id": "195950",
            "type": "article",
            "attributes": {
                "publishOn": "2010-03-29T10:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Shows Love for Targeted Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/195950-pfizer-shows-love-for-targeted-therapeutics"
            }
        },
        {
            "id": "191709",
            "type": "article",
            "attributes": {
                "publishOn": "2010-03-03T10:54:44-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Prevnar 13 Gains FDA Approval",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/191709-pfizers-prevnar-13-gains-fda-approval"
            }
        },
        {
            "id": "191588",
            "type": "article",
            "attributes": {
                "publishOn": "2010-03-03T02:17:04-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Newly Approved Vaccine Should Be Huge Growth Driver",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/191588-pfizers-newly-approved-vaccine-should-be-huge-growth-driver"
            }
        },
        {
            "id": "186583",
            "type": "article",
            "attributes": {
                "publishOn": "2010-02-04T05:53:19-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's New Alzheimer's Drug: A Black Box Indeed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/186583-pfizers-new-alzheimers-drug-a-black-box-indeed"
            }
        },
        {
            "id": "186355",
            "type": "article",
            "attributes": {
                "publishOn": "2010-02-03T11:29:39-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Earnings In-Line, Guidance Down",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/186355-pfizer-earnings-in-line-guidance-down"
            }
        },
        {
            "id": "185605",
            "type": "article",
            "attributes": {
                "publishOn": "2010-02-02T06:55:00-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Moves Toward Goal of Becoming Top-Tier Biotherapeutics Company",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/185605-pfizer-moves-toward-goal-of-becoming-top-tier-biotherapeutics-company"
            }
        },
        {
            "id": "184886",
            "type": "article",
            "attributes": {
                "publishOn": "2010-01-27T17:21:45-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Preview: Expect an Earnings Beat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22064",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/184886-pfizer-preview-expect-an-earnings-beat"
            }
        },
        {
            "id": "183850",
            "type": "article",
            "attributes": {
                "publishOn": "2010-01-22T05:57:30-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Sees Future Deals as China Biopharma Consolidates",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20840",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/183850-pfizer-sees-future-deals-as-china-biopharma-consolidates"
            }
        },
        {
            "id": "183124",
            "type": "article",
            "attributes": {
                "publishOn": "2010-01-19T04:55:58-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Long Case for Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "89228",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/183124-the-long-case-for-pfizer"
            }
        },
        {
            "id": "181781",
            "type": "article",
            "attributes": {
                "publishOn": "2010-01-12T04:29:00-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Expands Generics Portfolio with Indian Partnership",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23087",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/181781-pfizer-expands-generics-portfolio-with-indian-partnership"
            }
        },
        {
            "id": "180849",
            "type": "article",
            "attributes": {
                "publishOn": "2010-01-05T02:07:15-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Apo-A1 Milano Flop: Typical for Big Pharma Deals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/180849-pfizers-apo-a1-milano-flop-typical-for-big-pharma-deals"
            }
        },
        {
            "id": "180770",
            "type": "article",
            "attributes": {
                "publishOn": "2010-01-04T11:37:33-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "FDA Delay of Prevnar 13 Could Be Trouble for Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/180770-fda-delay-of-prevnar-13-could-be-trouble-for-pfizer"
            }
        }
    ]
}